S&P 500   5,149.42
DOW   38,790.43
QQQ   437.48
3 Large-Cap Stocks Buying Back Shares Aggressively
Semis, Nvidia Set for Big Moves as GTC Conference Kicks Off
Here’s Why Bitcoin Miners Stopped Rising With Bitcoin Prices
2 Deep Value, High Yield Stocks With a Double-Digit Upside
3 Stocks About to Boom on Unusual Call Option Volume
How major US stock indexes fared Monday, 3/18/2024
Oil Prices Up Again, Should You Buy This Time?
S&P 500   5,149.42
DOW   38,790.43
QQQ   437.48
3 Large-Cap Stocks Buying Back Shares Aggressively
Semis, Nvidia Set for Big Moves as GTC Conference Kicks Off
Here’s Why Bitcoin Miners Stopped Rising With Bitcoin Prices
2 Deep Value, High Yield Stocks With a Double-Digit Upside
3 Stocks About to Boom on Unusual Call Option Volume
How major US stock indexes fared Monday, 3/18/2024
Oil Prices Up Again, Should You Buy This Time?
S&P 500   5,149.42
DOW   38,790.43
QQQ   437.48
3 Large-Cap Stocks Buying Back Shares Aggressively
Semis, Nvidia Set for Big Moves as GTC Conference Kicks Off
Here’s Why Bitcoin Miners Stopped Rising With Bitcoin Prices
2 Deep Value, High Yield Stocks With a Double-Digit Upside
3 Stocks About to Boom on Unusual Call Option Volume
How major US stock indexes fared Monday, 3/18/2024
Oil Prices Up Again, Should You Buy This Time?
S&P 500   5,149.42
DOW   38,790.43
QQQ   437.48
3 Large-Cap Stocks Buying Back Shares Aggressively
Semis, Nvidia Set for Big Moves as GTC Conference Kicks Off
Here’s Why Bitcoin Miners Stopped Rising With Bitcoin Prices
2 Deep Value, High Yield Stocks With a Double-Digit Upside
3 Stocks About to Boom on Unusual Call Option Volume
How major US stock indexes fared Monday, 3/18/2024
Oil Prices Up Again, Should You Buy This Time?
NASDAQ:AYTU

Aytu BioPharma (AYTU) Stock Price, News & Analysis

$2.89
+0.02 (+0.70%)
(As of 03/18/2024 ET)
Today's Range
$2.82
$3.11
50-Day Range
$2.46
$3.28
52-Week Range
$1.38
$3.50
Volume
62,253 shs
Average Volume
20,437 shs
Market Capitalization
$16.10 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.00

Aytu BioPharma MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
73.0% Upside
$5.00 Price Target
Short Interest
Bearish
6.52% of Float Sold Short
Dividend Strength
N/A
Sustainability
-2.45
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.31 out of 5 stars

Medical Sector

301st out of 947 stocks

Pharmaceutical Preparations Industry

142nd out of 435 stocks

AYTU stock logo

About Aytu BioPharma Stock (NASDAQ:AYTU)

Aytu Biopharma, Inc., a commercial-stage pharmaceutical company, focuses on commercializing novel therapeutics and consumer healthcare products the United States and internationally. The company operates through two segments: Rx segment and Consumer Health segment. The Rx segment offers prescription products for the treatment of attention deficit hyperactivity disorder (ADHD), including Adzenys XR-ODT for patients from six years and older, and Cotempla XR-ODT for patients from six to seventeen years old. The segment also provides pediatric prescription product portfolio comprising Karbinal ER, an extended-release carbinoxamine (antihistamine) suspension indicated to treat numerous allergic conditions for patients two years and above; and Poly-Vi-Flor and Tri-Vi-Flor complementary prescription fluoride-based multi-vitamin products containing combinations of fluoride and vitamins in liquid and chewable tablet form for infants and children with fluoride deficiency. The Consumer Health segment is involved in the commercialization of over-the-counter medicines, personal care products, and dietary supplements in various categories, such as hair loss, digestive health, urological health, diabetes management, and allergy. The segment offers Regoxidine - for Men and Women, a proprietary over-the-counter aerosol foam that works to treat hair loss in both men and women; and OmepraCareDR and EsomepraCareDR, acid reducers for the treatment of frequent heartburn. It also engages in the development of AR101 (enzastaurin), an orally available investigational first-in-class small molecule, serine/threonine kinase inhibitor targeting the treatment of vascular Ehlers-Danlos Syndrome. The company was formerly known as Aytu BioScience, Inc. and changed its name to Aytu Biopharma, Inc. in March 2021. Aytu Biopharma, Inc. is based in Denver, Colorado.

AYTU Stock Price History

AYTU Stock News Headlines

Claim Your Complimentary Bitcoin Reward
Many have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.
Q2 2024 Aytu Biopharma Inc Earnings Call
Earnings Preview: Aytu BioPharma
They said crypto was dead. It went up 100X.
Bitcoin’s haters are out again. Despite the price doubling in the last six months alone… That hasn’t stopped the experts from piling on. Warren Buffett’s right-hand man Charlie Munger called crypto investors “idiots” in one of his last interviews. JPMorgan CEO Jamie Dimon, recently called Bitcoin a “pet rock” and “a hyped-up fraud.” But when it comes to cryptos, these are exactly the people you shouldn’t listen to. They’ve predicted crypto’s demise for years.
Aytu BioPharma earnings: here's what to expect
See More Headlines
Receive AYTU Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aytu BioPharma and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/14/2024
Today
3/18/2024
Next Earnings (Estimated)
5/09/2024
Fiscal Year End
6/30/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:AYTU
Fax
N/A
Employees
150
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$5.00
High Stock Price Target
$5.00
Low Stock Price Target
$5.00
Potential Upside/Downside
+73.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-17,050,000.00
Pretax Margin
-17.43%

Debt

Sales & Book Value

Annual Sales
$107.40 million
Cash Flow
$0.99 per share
Book Value
$10.41 per share

Miscellaneous

Free Float
5,326,000
Market Cap
$16.10 million
Optionable
Not Optionable
Beta
-1.21
Beginners Guide To Retirement Stocks Cover

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Mr. Joshua R. Disbrow (Age 49)
    Chairman & CEO
    Comp: $708k
  • Mr. Mark K. Oki CPA (Age 55)
    CFO, Secretary & Treasurer
    Comp: $522.84k
  • Mr. Greg Pyszczymuka (Age 45)
    Chief Commercial Officer
    Comp: $525k
  • Ms. Victoria Cordova
    Vice President of People & Culture
  • Mr. Jarrett T. Disbrow Ph.D. (Age 49)
    Chief Business Officer & President of Consumer Health
    Comp: $355k
  • Mr. Russ McMahen
    Senior Vice President of Research & Development
  • Mr. Ryan J. Selhorn CPA (Age 42)
    Executive VP of Finance & Business Optimization

AYTU Stock Analysis - Frequently Asked Questions

Should I buy or sell Aytu BioPharma stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Aytu BioPharma in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" AYTU shares.
View AYTU analyst ratings
or view top-rated stocks.

What is Aytu BioPharma's stock price target for 2024?

1 equities research analysts have issued twelve-month price targets for Aytu BioPharma's shares. Their AYTU share price targets range from $5.00 to $5.00. On average, they predict the company's share price to reach $5.00 in the next year. This suggests a possible upside of 73.0% from the stock's current price.
View analysts price targets for AYTU
or view top-rated stocks among Wall Street analysts.

How have AYTU shares performed in 2024?

Aytu BioPharma's stock was trading at $2.84 at the beginning of 2024. Since then, AYTU stock has increased by 1.8% and is now trading at $2.89.
View the best growth stocks for 2024 here
.

When is Aytu BioPharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our AYTU earnings forecast
.

How were Aytu BioPharma's earnings last quarter?

Aytu BioPharma, Inc. (NASDAQ:AYTU) released its earnings results on Wednesday, February, 14th. The company reported ($0.04) earnings per share for the quarter. The firm earned $22.93 million during the quarter. Aytu BioPharma had a negative net margin of 18.27% and a negative trailing twelve-month return on equity of 41.00%.

When did Aytu BioPharma's stock split?

Aytu BioPharma shares reverse split on the morning of Tuesday, August 29th 2017. The 1-20 reverse split was announced on Friday, August 25th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Monday, August 28th 2017. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

What other stocks do shareholders of Aytu BioPharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Aytu BioPharma investors own include Sorrento Therapeutics (SRNE), Vaxart (VXRT), ADMA Biologics (ADMA), Heat Biologics (HTBX), Inovio Pharmaceuticals (INO), VBI Vaccines (VBIV), iBio (IBIO), Matinas BioPharma (MTNB), Bionano Genomics (BNGO) and SCYNEXIS (SCYX).

Who are Aytu BioPharma's major shareholders?

Aytu BioPharma's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (0.49%), Vanguard Group Inc. (0.49%), Goldman Sachs Group Inc. (0.25%), Goldman Sachs Group Inc. (0.25%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Greg Pyszczymuka and Joshua R Disbrow.
View institutional ownership trends
.

How do I buy shares of Aytu BioPharma?

Shares of AYTU stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:AYTU) was last updated on 3/18/2024 by MarketBeat.com Staff

From Our Partners